Faculty, Staff and Student Publications

Publication Date

8-1-2025

Journal

Cureus

DOI

10.7759/cureus.91355

PMID

41041106

PMCID

PMC12483835

PubMedCentral® Posted Date

8-31-2025

PubMedCentral® Full Text Version

Post-print

Abstract

High-dose olanzapine has shown efficacy in treating adult patients with treatment-resistant schizophrenia, though evidence in adolescents remains limited. This report describes the case of a 17-year-old male patient with treatment-resistant schizophrenia who showed significant clinical improvement with a supratherapeutic dose of orally disintegrating olanzapine. The patient, with a 16-month history of schizophrenia and multiple hospitalizations, presented with acute psychosis and aggression after medication non-adherence. Following failed trials of paliperidone and standard-dose olanzapine, and unable to initiate clozapine due to blood draw refusal, the patient was gradually titrated to 50 mg daily of orally disintegrating olanzapine (20 mg early morning, 30 mg at bedtime). This intervention marked improvements in thought process, thought content, and paranoia, with minimal side effects. This case adds to the limited literature on high-dose olanzapine in adolescents. It suggests that supratherapeutic doses may be a viable option for treatment-resistant cases in which standard treatments are ineffective or unfeasible.

Keywords

adolescent psychosis, antipsychotic therapy, clozapine alternatives, high dose olanzapine, orally disintegrating tablets, pediatric schizophrenia, schizophrenia treatment, second generation antipsychotics, supratherapeutic dosing, treatment resistant schizophrenia

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.